TRIM21 and systemic sclerosis: In 2021, the Canadian scleroderma research team once more reported positive rate results for anti-TRIM21 in 26% of 1,698 SSc patients, marking the most extensive cohort analysis of anti-TRIM21 in SSc to date, and crucially, this aligns closely with the UK’s reported rate of anti-TRIM21 positivity in 1,010 SSc patients (27%), Table 2 (117, 123).